cd22 car-transduced t cells
Lymphoma, B-Cell
Kecellitics Biotech Company LtdCell therapyPhase 1/2Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 73/ 100
Competitive context
50 Active assets in the Lymphoma, B-Cell cohort.
View all 50 →
Same molecule, other indications
cd22 car-transduced t cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →